Lifecore Biomedical, Inc. reported its financial results for the third quarter of 2026, revealing a significant decline in revenue and an increased net loss. The results highlight the ongoing challenges faced by the company as it navigates the competitive landscape of the pharmaceutical preparations industry.

On November 4, 2026, Lifecore announced its consolidated financial results for the third quarter and nine months ended September 30, 2026. The company reported revenues of $25.3 million for the third quarter, a decrease of $5.8 million, or 18.6%, compared to $31.1 million in the same quarter of the previous year. For the nine-month period, revenues totaled $82.7 million, down 21.8% from $105.7 million in the prior year.

Despite the revenue decline, Lifecore secured two new technology transfer projects during the third quarter, which are expected to contribute to the company's long-term revenue growth starting in 2027. CEO Paul Josephs emphasized the importance of these new projects in a press release, stating, “We believe these programs will add to Lifecore’s high-value pipeline.”

Founded in Delaware, Lifecore Biomedical operates as a fully integrated injectables contract development and manufacturing organization. The company is listed on the Nasdaq under the ticker symbol LFCR. As a part of the pharmaceutical preparations sector, Lifecore's performance is closely monitored by industry analysts and competitors alike.

The filing, which includes detailed financial statements and exhibits, indicates that the company's gross profit for the third quarter was $6.8 million, a decrease from $7.8 million in the same quarter last year. Operating expenses also decreased to $7.7 million, down 28.9% from the prior year.

However, Lifecore reported a net loss of $40.1 million, or $1.08 loss per diluted share, compared to a net loss of $10.0 million, or $0.29 loss per diluted share, for the same period in 2025. For the nine months ended September 30, 2026, the net loss was $61.2 million, significantly higher than the $20.9 million loss reported for the same period last year.

Looking ahead, Lifecore ended the third quarter with approximately $38.0 million in liquidity, including $23.0 million in cash and $15.0 million in revolving credit availability. This financial cushion may provide the company with the necessary resources to invest in its new projects and navigate the current economic challenges.

As Lifecore continues to secure new business opportunities, the industry will be watching closely to see how these developments impact its financial performance in the coming quarters. The filing does not specify what actions the company will take next, but the focus on new projects suggests a proactive approach to recovery.